CASP10 and triple-negative breast carcinoma: At the higher concentration (3 μM) of the tested compound, an over 7-fold (10.0 ± 0.5%) in MCF-7 breast cancer cells and an approximately 3-fold (15.5 ± 2.7%) in MDA-MB-231 triple-negative breast cancer cells increase in caspase 10 activity compared with the control was reported.